On to the FDA With a New Name: "Advanced Magnetics (Nasdaq: AMAG) announced phase 3 clinical trial results earlier this week. Not surprisingly, the results were consistent with the three other previous trials.
The most recent trial compared ferumoxytol, an intravenous iron replacement therapeutic, to iron taken orally in anemic patients with chronic kidney disease (CKD) who are on hemodialysis. Iron is required for the production of red blood cells, a deficiency in which leads to anemia. Ferumoxytol raised the amount of hemoglobin -- an indirect measure of iron levels -- in the patients significantly more than oral administration of iron, resulting in the trial meeting its primary endpoint."
